Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Nov 19, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Nov 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, press-release
TL;DR
Innate Pharma filed a 6-K, likely with a press release. No major news here, just procedural.
AI Summary
Innate Pharma SA filed a Form 6-K on November 19, 2024, to report a press release dated the same day. The filing does not contain specific financial figures or operational updates in the provided text, but indicates the company is a foreign private issuer based in Marseille, France.
Why It Matters
This filing serves as a notification to the SEC about a press release, which may contain important updates for investors regarding the company's operations or strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a press release and does not contain new material financial or operational information that would inherently increase risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- November 19, 2024 (date) — Filing and Press Release Date
- Marseille, France (location) — Company Headquarters
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release issued by Innate Pharma SA on November 19, 2024, as required for foreign private issuers.
Where is Innate Pharma SA headquartered?
Innate Pharma SA is headquartered in Marseille, France.
What is the filing date of this report?
The filing date of this report is November 19, 2024.
Does Innate Pharma SA file annual reports under Form 20-F or 40-F?
Innate Pharma SA indicates that it files annual reports under Form 20-F.
What exhibit is included with this 6-K filing?
The included exhibit is a Press Release dated November 19, 2024, designated as Exhibit 99.1.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-11-19 06:01:20
Filing Documents
- a6k-iphx241119.htm (6-K) — 8KB
- exhibit991-241119.htm (EX-99.1) — 21KB
- 0001598599-24-000089.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date November 19, 2024 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chairman of the Executive Board and Chief Executive officer